These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10468291)

  • 1. Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates.
    Jackson TL; Lubkin SR; Siemers NO; Kerr DE; Senter PD; Murray JD
    Br J Cancer; 1999 Aug; 80(11):1747-53. PubMed ID: 10468291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical analysis of conjugate localization in two-step cancer chemotherapy.
    Jackson TL; Lubkin SR; Murray JD
    J Math Biol; 1999 Oct; 39(4):353-76. PubMed ID: 10550578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
    Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
    Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
    Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates.
    Carcenac M; Larroque C; Langlois R; van Lier JE; Artus JC; Pèlegrin A
    Photochem Photobiol; 1999 Dec; 70(6):930-6. PubMed ID: 10628305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).
    Varner JD
    Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
    Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
    McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
    Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.
    Kerr DE; Vrudhula VM; Svensson HP; Siemers NO; Senter PD
    Bioconjug Chem; 1999; 10(6):1084-9. PubMed ID: 10563779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    Scott AM; Lee FT; Hopkins W; Cebon JS; Wheatley JM; Liu Z; Smyth FE; Murone C; Sturrock S; MacGregor D; Hanai N; Inoue K; Yamasaki M; Brechbiel MW; Davis ID; Murphy R; Hannah A; Lim-Joon M; Chan T; Chong G; Ritter G; Hoffman EW; Burgess AW; Old LJ
    J Clin Oncol; 2001 Oct; 19(19):3976-87. PubMed ID: 11579119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
    Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
    Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
    Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.